1. Search Result
Search Result
Results for "

Y 6

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

3

Peptides

3

Natural
Products

3

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1322

    Neuropeptide Y Receptor Neurological Disease
    [D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats .
    [D-Trp34]-Neuropeptide Y
  • HY-137294

    Y6

    Others Others
    BTPTT-4F (Y6) is a non-fullerene acceptor-donor-acceptor (A-D-A) type small molecular acceptor (SMA) characterized by its flexible alkyl chains and centrally fused ring structure. Featuring a ladder-type electron-deficient core, BTPTT-4F can be effectively blended with PM6, showcasing significant potential for enhancing the performance of organic photovoltaic applications. Its tailored optical properties and adjustable electronic energy levels contribute to improved thermal and photochemical stability, making it a promising candidate for next-generation high-performance organic solar cells.
    BTPTT-4F
  • HY-117465

    Others Cancer
    HAC-Y6 has anticancer activity via cell cycle arrest. HAC-Y6 induces apoptosis in COLO 205 cells with an IC50 of 0.52 µM .
    HAC-Y6
  • HY-168098

    P2Y Receptor Inflammation/Immunology
    P2Y6R antagonist 1 (compound 5ab) is a selective, orally active P2Y6R antagonist with an IC50 value of 19.6 nM. P2Y6R antagonist 1 has anti-inflammatory activity .
    P2Y6R antagonist 1
  • HY-157444

    HIF/HIF Prolyl-Hydroxylase Cancer
    5,3',4',3'',4'',5''-6-O-Ethyl-EGCG (Y6) is a potent adjuvant obtained by optimization of the structure of EGCG. 5,3',4',3'',4'',5''-6-O-Ethyl-EGCG (Y6) decreases the expression of HIF-1α and CBR1 at both the mRNA and protein levels .
    5,3',4',3'',4'',5''-6-O-Ethyl-EGCG
  • HY-P1322A

    Neuropeptide Y Receptor Neurological Disease
    [D-Trp34]-Neuropeptide Y TFA is a potent and selective neuropeptide Y (NPY) Y5 receptor agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y TFA markedly increases food intake in rats .
    [D-Trp34]-Neuropeptide Y TFA
  • HY-P1321

    1229U91; GW1229

    Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-113359

    P2Y Receptor Endogenous Metabolite Others
    Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor .
    Uridine 5'-diphosphate
  • HY-108650

    2-Thiouridine 5′-triphosphate tetrasodium

    P2Y Receptor Cancer
    2-Thio-UTP tetrasodium is a potent P2Y2, P2Y4 and P2Y6 agonist, which an be used for the research of cancer .
    2-Thio-UTP tetrasodium
  • HY-113359AS3

    Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor Others
    Uridine 5'-diphosphate- 15N2 dilithium is 15N labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor.
    Uridine 5'-diphosphate-15N2 dilithium
  • HY-113359AS1

    Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor Others
    Uridine 5'-diphosphate- 13C9 dilithium is 13C-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor.
    Uridine 5'-diphosphate-13C9 dilithium
  • HY-108663

    5-Methoxyuridine 5'-trihydrogen diphosphate

    P2Y Receptor Neurological Disease Metabolic Disease
    5-OMe-UDP (5-methoxyuridine 5'-trihydrogen diphosphate) is a P2Y6 receptor agonist (EC50=0.08 μM). 5-OMe-UDP activates the P2Y6 receptor by binding to it, which triggers signaling pathways within the cell. This activation can lead to an increase in intracellular calcium ion concentration, which in turn regulates cellular function. The methoxy groups of 5-OMe-UDP provide additional activity and selectivity, contributing to the binding of 5-OMe-UDP to the P2Y6 receptor. 5-OMe-UDP can be used to study diseases related to P2Y6 receptor function, such as diabetes, inflammatory bowel disease, Alzheimer's disease, etc .
    5-OMe-UDP
  • HY-113359AS2

    Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor Others
    Uridine 5'-diphosphate- 13C9, 15N2 dilithium is 13C and 15N-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y6 receptor agonist with an EC50 of 0.013 μM for human P2Y6 receptor.
    Uridine 5'-diphosphate-13C9,15N2 dilithium
  • HY-13104
    MRS 2578
    Maximum Cited Publications
    6 Publications Verification

    P2Y Receptor Apoptosis Cardiovascular Disease
    MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors .
    MRS 2578
  • HY-W010832
    Uridine-5'-diphosphate disodium salt
    1 Publications Verification

    P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Uridine-5'-diphosphate disodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52 for human P2Y6 receptor). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis .
    Uridine-5'-diphosphate disodium salt
  • HY-110322A

    P2Y Receptor Inflammation/Immunology
    PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
    PPTN
  • HY-110322
    PPTN hydrochloride
    2 Publications Verification

    P2Y Receptor Inflammation/Immunology
    PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .
    PPTN hydrochloride
  • HY-103055

    P2Y Receptor Inflammation/Immunology
    PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
    PPTN mesylate
  • HY-110092

    P2Y Receptor Metabolic Disease
    PSB-1114 tetrasodium is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 tetrasodium displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors .
    PSB-1114 tetrasodium
  • HY-110092A

    P2Y Receptor Cancer
    PSB-1114 triethylamine is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 triethylamine displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors .
    PSB-1114 triethylamine
  • HY-131821

    Thymidine-5'-O-monophosphorothioate

    P2Y Receptor Others
    5'-TMPS (Thymidine-5'-O-monophosphorothioate) is a selective partial agonist of P2Y6R and an antagonist of P2Y14R. Additionally, 5'-TMPS acts as a positive regulator of angiogenesis, exhibiting pro-angiogenic effects
    5'-TMPS
  • HY-108664

    Others Metabolic Disease
    MRS2957 is a P2Y6 receptor agonist that activates AMPK in pancreatic β-cells, promoting insulin secretion and reducing apoptosis, thereby holding potential as a therapeutic target for type 2 diabetes.
    MRS2957
  • HY-101308

    P2Y Receptor Cardiovascular Disease
    MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .
    MRS2179 tetrasodium
  • HY-101308A
    MRS2179 tetrasodium hydrate
    1 Publications Verification

    P2Y Receptor Cardiovascular Disease
    MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .
    MRS2179 tetrasodium hydrate
  • HY-108648

    2-Methylthioadenosine diphosphate trisodium; 2-Methylthio-ADP trisodium

    P2Y Receptor Neurological Disease
    2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .
    2-MeS-ADP trisodium
  • HY-108648A

    2-Methylthioadenosine diphosphate; 2-Methylthio-ADP

    P2Y Receptor Neurological Disease
    2-MeSADP (2-Methylthioadenosine diphosphate; 2-Methylthio-ADP) is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-MeSADP has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-MeSADP induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .
    2-MeSADP
  • HY-108654

    P2Y Receptor Apoptosis Neurological Disease
    PSB 0474 (3-phenacyl-UDP) is a selective and potent P2Y6 receptor agonist with an EC50 of 70 nM . PSB 0474 inhibits cell proliferation, increases NO release in astrocytes and microglia cells. PSB 0474 induces astrocytes apoptosis .
    PSB 0474
  • HY-137608

    UDP-β-S

    P2Y Receptor Cardiovascular Disease
    Uridine 5'-O-thiodiphosphate (UDP-β-S) is a stable analog of UDP. As a selective agonist of P2Y6 receptor, Uridine 5'-O-thiodiphosphate has higher metabolic stability and can be used in the study of cardiovascular diseases .
    Uridine 5'-O-thiodiphosphate
  • HY-W010820

    P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Uridine 5'-diphosphate sodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52) and a potent P2Y14 antagonist (pEC50=7.28). Uridine 5'-diphosphate sodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis .
    Uridine 5'-diphosphate sodium salt
  • HY-117356B

    P2Y Receptor NF-κB ERK Cardiovascular Disease
    MRS2693 trisodium is a selective P2Y6 agonist with an EC50 value of 0.015 μM. MRS2693 trisodium can reduce the activation of NF-kappaB and activate the ERK1/2 pathway, and has a cytoprotective effect on mouse hindlimb skeletal muscle ischemia-reperfusion injury model .
    MRS2693 trisodium
  • HY-117356A

    P2Y Receptor NF-κB ERK Apoptosis Inflammation/Immunology
    MRS2693 ammonium is the ammonium dalt form of MRS2693 (HY-117356). MRS2693 ammonium is a selective agonist for P2Y6 with an EC50 of 0.015 μM. MRS2693 ammonium protects C2C12 skeletal muscle cells from TNFα-induced apoptosis. MRS2693 ammonium reduces the activation of NF-kB, activates the ERK1/2 pathway, and has a cytoprotective effect on mouse ischemia-reperfusion injury model [2].
    MRS2693 ammonium
  • HY-134807

    P2X Receptor 5-HT Receptor Autophagy Cancer
    Indophagolin is a potent, indoline-containing autophagy inhibitor (IC50=140 nM). Indophagolin antagonizes the purinergic receptor P2X4 as well as P2X1 and P2X3 with IC50s of 2.71, 2.40 and 3.49 μM, respectively. Indophagolin also antagonizes the Gq-protein-coupled P2Y4, P2Y6, and P2Y11 receptors (IC50s =3.4~15.4 μM). Indophagolin has a strong antagonistic effect on serotonin receptor 5-HT6 (IC50=1.0 μM) and a moderate effect on receptors 5-HT1B, 5-HT2B, 5-HT4e, and 5-HT7 .
    Indophagolin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: